$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000106282215000025 Filed on May 05, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$1.792M	$277.0K
YoY Change	546.93%	-23.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.700M	$5.300M
YoY Change	7.55%	23.26%
% of Gross Profit
Research & Development	$20.87M	$23.95M
YoY Change	-12.89%	17.84%
% of Gross Profit
Depreciation & Amortization	$355.0K	$644.0K
YoY Change	-44.88%	-18.79%
% of Gross Profit
Operating Expenses	$28.32M	$30.75M
YoY Change	-7.9%	18.65%
Operating Profit	-$26.53M	-$30.47M
YoY Change	-12.95%	19.24%
Interest Expense	$1.702M	$457.0K
YoY Change	272.43%	-9.68%
% of Operating Profit
Other Income/Expense, Net	$153.0K	$94.00K
YoY Change	62.77%	176.47%
Pretax Income	-$28.10M	-$30.80M
YoY Change	-8.77%	18.46%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$28.08M	-$30.84M
YoY Change	-8.95%	18.71%
Net Earnings / Revenue	-1566.74%	-11131.77%
Basic Earnings Per Share	-$0.27
Diluted Earnings Per Share	-$0.27	-$419.6K
COMMON SHARES
Basic Shares Outstanding	103.5M shares	513.8M shares
Diluted Shares Outstanding	103.5M shares

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$314.7M	$97.90M
YoY Change	221.45%	-50.23%
Cash & Equivalents	$41.96M	$46.52M
Short-Term Investments	$272.7M	$51.40M
Other Short-Term Assets	$3.194M	$6.570M
YoY Change	-51.39%	-22.14%
Inventory
Prepaid Expenses
Receivables	$170.0K	$471.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$342.3M	$105.4M
YoY Change	224.75%	-48.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$732.0K	$39.96M
YoY Change	-98.17%	-6.25%
Goodwill	$44.54M	$44.54M
YoY Change	0.0%	0.0%
Intangibles	$53.36M	$53.56M
YoY Change	-0.37%	0.0%
Long-Term Investments
YoY Change
Other Assets	$3.740M	$133.0K
YoY Change	2712.03%	51.14%
Total Long-Term Assets	$102.4M	$138.2M
YoY Change	-25.92%	-1.86%
TOTAL ASSETS
Total Short-Term Assets	$342.3M	$105.4M
Total Long-Term Assets	$102.4M	$138.2M
Total Assets	$444.7M	$243.6M
YoY Change	82.55%	-29.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.14M	$7.072M
YoY Change	71.69%	29.95%
Accrued Expenses	$11.77M	$7.952M
YoY Change	48.0%	-18.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.71M	$1.746M
YoY Change	1028.92%	8.65%
Total Short-Term Liabilities	$45.93M	$17.67M
YoY Change	159.9%	1.68%
LONG-TERM LIABILITIES
Long-Term Debt	$87.50M	$19.71M
YoY Change	343.91%	-8.14%
Other Long-Term Liabilities	$23.26M	$34.02M
YoY Change	-31.63%	-0.18%
Total Long-Term Liabilities	$110.8M	$53.73M
YoY Change	106.15%	-3.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.93M	$17.67M
Total Long-Term Liabilities	$110.8M	$53.73M
Total Liabilities	$187.1M	$102.8M
YoY Change	81.94%	-2.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.132B	-$1.035B
YoY Change	9.43%	11.77%
Common Stock	$727.0K	$516.0K
YoY Change	40.89%	0.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.747M	$2.390M
YoY Change	14.94%	59.02%
Treasury Stock Shares	1.662M shares	1.281M shares
Shareholders Equity	$257.6M	$140.8M
YoY Change
Total Liabilities & Shareholders Equity	$444.7M	$243.6M
YoY Change	82.55%	-29.85%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$28.08M	-$30.84M
YoY Change	-8.95%	18.71%
Depreciation, Depletion And Amortization	$355.0K	$644.0K
YoY Change	-44.88%	-18.79%
Cash From Operating Activities	-$23.49M	-$30.32M
YoY Change	-22.54%	24.92%
INVESTING ACTIVITIES
Capital Expenditures	$17.00K	$28.00K
YoY Change	-39.29%	-96.66%
Acquisitions
YoY Change
Other Investing Activities	-$71.00M	$40.60M
YoY Change	-274.88%	35.79%
Cash From Investing Activities	-$70.99M	$40.57M
YoY Change	-274.99%	39.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$357.0K	$811.0K
YoY Change	-55.98%	29.97%
Debt Paid & Issued, Net	$456.0K	$420.0K
YoY Change	8.57%	8.53%
Cash From Financing Activities	-$830.0K	-$1.231M
YoY Change	-32.58%	21.76%
NET CHANGE
Cash From Operating Activities	-$23.49M	-$30.32M
Cash From Investing Activities	-$70.99M	$40.57M
Cash From Financing Activities	-$830.0K	-$1.231M
Net Change In Cash	-$95.31M	$9.018M
YoY Change	-1156.84%	135.76%
FREE CASH FLOW
Cash From Operating Activities	-$23.49M	-$30.32M
Capital Expenditures	$17.00K	$28.00K
Free Cash Flow	-$23.50M	-$30.35M
YoY Change	-22.56%	20.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	725294841	shares
CY2015Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE
CY2015Q1	lxrx	Buildings Collateral BuildingsCollateral	59100000	USD
CY2014Q1	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1142000	USD
CY2015Q1	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1753000	USD
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q2	lxrx	Common Stock Shares Authorized After Reverse Stock Split CommonStockSharesAuthorizedAfterReverseStockSplit	225000000	shares
CY2014Q4	lxrx	Convertible Debt Instrument Interest Rate Stated Percentage ConvertibleDebtInstrumentInterestRateStatedPercentage	0.0525
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2014Q4	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	34000000	USD
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
CY2015Q1	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
CY2015Q1	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	1700000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2015Q1	lxrx	Land Collateral LandCollateral	2700000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	7650622	shares
CY2014Q1	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	792000	USD
CY2015Q1	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	849000	USD
CY2014Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1458000	USD
CY2015Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1104000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	13237519	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2014Q4	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	5800000	USD
CY2015Q2	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	750000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2014Q4	lxrx	Symphony Contingent Payment Total SymphonyContingentPaymentTotal	11500000	USD
CY2014Q4	lxrx	Symphony Contingent Paymentin Shares SymphonyContingentPaymentinShares	4662780	shares
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13064000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12142000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1035000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	170000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10120000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11769000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36274000	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	35899000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-63000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	23000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1389997000	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1391932000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2250000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1953000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2300000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2000000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	62000	USD
CY2014Q4	us-gaap	Assets Assets	471376000	USD
CY2015Q1	us-gaap	Assets Assets	444682000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9018000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	368987000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	342310000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37499000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46517000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137266000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41960000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-95306000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	726000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	727000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30827000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27990000	USD
CY2014Q1	us-gaap	Contracts Revenue ContractsRevenue	172000	USD
CY2015Q1	us-gaap	Contracts Revenue ContractsRevenue	1792000	USD
CY2015Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	87500000	USD
CY2015Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1618000	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2311000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12679000	USD
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	11708000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
CY2015Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	644000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	355000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1142000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1753000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-750000	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	27710000	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	28852000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17638000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	18641000	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-264000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	6000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5654000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5701000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2015Q1	us-gaap	Goodwill Goodwill	44543000	USD
CY2015Q1	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	4500000	USD
CY2014Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	242000	USD
CY2015Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-393000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1934000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	278000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	11000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1876000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1302000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-319000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-865000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	18000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1570000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	457000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	1702000	USD
CY2014Q1	us-gaap	Interest Paid Net InterestPaidNet	447000	USD
CY2015Q1	us-gaap	Interest Paid Net InterestPaidNet	412000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	187358000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	187075000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	471376000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	444682000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44969000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	45933000	USD
CY2014Q1	us-gaap	Licenses Revenue LicensesRevenue	105000	USD
CY2015Q1	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	20167000	USD
CY2015Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	19711000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	87500000	USD
CY2015Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	87500000	USD
CY2015Q1	us-gaap	Mortgage Loans On Real Estate Carrying Amount Of Mortgages MortgageLoansOnRealEstateCarryingAmountOfMortgages	19700000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1231000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-830000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	40568000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70991000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30319000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23485000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-30835000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-28076000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	30749000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	28319000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-30472000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26527000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4764000	USD
CY2015Q1	us-gaap	Other Assets Current OtherAssetsCurrent	3194000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3409000	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3740000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	8000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	86000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23535000	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23259000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	94000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	153000	USD
CY2014Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	887000	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	357000	USD
CY2014Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20651000	USD
CY2015Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	70978000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	76000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2015Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-17000	USD
CY2014Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	60438000	USD
CY2015Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	809000	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1080000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	732000	USD
CY2014Q4	us-gaap	Real Estate Heldforsale RealEstateHeldforsale	23849000	USD
CY2015Q1	us-gaap	Real Estate Heldforsale RealEstateHeldforsale	23849000	USD
CY2014Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2015Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	420000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	456000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23953000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20865000	USD
CY2014Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2015Q1	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1104252000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1132328000	USD
CY2014Q1	us-gaap	Revenues Revenues	277000	USD
CY2015Q1	us-gaap	Revenues Revenues	1792000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2250000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1953000	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	202073000	USD
CY2015Q1	us-gaap	Short Term Investments ShortTermInvestments	273137000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	76000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	284018000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	257607000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	170163000	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	140775000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	284018000	USD
CY2015Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	257607000	USD
CY2015Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	-17000	USD
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1281000	shares
CY2015Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1662000	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2390000	USD
CY2015Q1	us-gaap	Treasury Stock Value TreasuryStockValue	2747000	USD
CY2014Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	887000	USD
CY2015Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	357000	USD
CY2015Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3200000	USD
CY2014Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	8000	USD
CY2015Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	86000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	513955000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	724613000	shares

Files In Submission

Name	View Source	Status
0001062822-15-000025-index-headers.html	Edgar Link	pending
0001062822-15-000025-index.html	Edgar Link	pending
0001062822-15-000025.txt	Edgar Link	pending
0001062822-15-000025-xbrl.zip	Edgar Link	pending
exh101ipsenagreement.htm	Edgar Link	pending
exh102bmsagreement.htm	Edgar Link	pending
exh103bmsagreeementamendme.htm	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrx-20150331.xml	Edgar Link	completed
lxrx-20150331.xsd	Edgar Link	pending
lxrx-20150331_cal.xml	Edgar Link	unprocessable
lxrx-20150331_def.xml	Edgar Link	unprocessable
lxrx-20150331_lab.xml	Edgar Link	unprocessable
lxrx-20150331_pre.xml	Edgar Link	unprocessable
lxrx331201510-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2015 Q1 Form 10-Q Financial Statement

#000106282215000025 Filed on May 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2015 Q1 Form 10-Q Financial Statement

#000106282215000025 Filed on May 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx